— First webinar to cover evidence report for Alzheimer’s disease—
BOSTON, June 24, 2021 – The Institute for Clinical and Economic Review (ICER) today announced an upcoming webinar series facilitated by FormularyDecisions® to provide early insights into ongoing ICER research, and to demonstrate how ICER Analytics™ is helping health care decision makers use this research in new ways to develop formularies, negotiate drug prices, and ultimately, pursue policies that promote fair pricing and fair access.
ICER’s first webinar will occur on July 29, 2021 at 12:00 p.m. EDT. During this initial webinar, ICER’s President Steven D. Pearson, MD, MSc, will discuss the key findings and policy ramifications of our Evidence Report on Alzheimer’s disease. Going forward, in these webinars, ICER plans to present early insights from its reports shortly after the posting of the initial draft version.
ICER leaders will also discuss and demonstrate how key stakeholders – payers, life science companies, patient groups, and other health technology assessment organizations around the world – are able to use ICER Analytics to quickly translate this type of research into evidence-based, patient-centered policies. ICER will also introduce its new white glove service for trial users and new subscribers to ICER Analytics. This service includes personalized orientation sessions to maximize the benefits of ICER Analytics and Q&A briefings with ICER leadership.
ICER’s Early Insights Webinar Series will be hosted via the FormularyDecisions platform, a secure online platform from AmerisourceBergen that facilities the exchange of information between payers and life sciences companies to support medical policy and formulary development. Future Early Insights webinars are planned later this year in myasthenia gravis, hypertrophic cardiomyopathy, and asthma.
Register to attend the July 29th webinar on Alzheimer’s disease here.
About ICER Analytics
While all of ICER’s reports will remain in the public domain as downloadable PDFs from our website, ICER Analytics is a cloud-based platform that comprises two tools geared toward frequent users of ICER’s research:
- The ICER Evidence Compendium™ is a rapidly searchable and sortable summary of results from ICER’s library of evidence reports. In addition to the clinical effectiveness ratings and pricing benchmarks for each drug and indication, the Evidence Compendium allows users to enter their own pricing to compare to ICER price benchmarks. To help support internal assessments by payers and their Pharmacy & Therapeutics (P&T) committees, the Evidence Compendium has a separate section containing exclusive curated report material and videos from ICER appraisal committee meetings, including narrative summaries of insights gained from patients, key evidence tables, comparative clinical effectiveness votes, expert testimony from clinicians and patients on broader dimensions of value, and perspectives on potential coverage criteria and pricing policy.
- The ICER Interactive Modeler™ provides access to a growing set of ICER economic models, all of which will be customizable by the end user. The Interactive Modeler provides users with a deeper understanding of ICER’s models and architecture, as well as the ability to insert their own prices, their own data on patient characteristics, or their own assumptions about drug performance and uptake. Payers will be able to perform multiple iterations to explore the impact on health outcomes and budget impact. Life science companies will be able to “publish” their own alternative cost-effectiveness findings into the ICER Evidence Compendium so that payers will see both the original ICER results and those of the manufacturer side-by-side.
ICER Analytics is available through ICER and FormularyDecisions. FormularyDecisions is a secure online platform facilitating the bi-directional exchange of information between life sciences companies and healthcare decision makers (HCDMs). This closed, HCDM-only platform supports over 2,500 registered, active, formulary decision makers with clinical and economic information on >3,000 pre- and post-approval products. ICER’s Interactive Modeler is powered by Digital Health Outcomes, a global leader in designing software to help unlock the true potential of health economics models by allowing users to easily adapt input data and interpret results for their decision-making.
Potential users can request more information about ICER Analytics here.
What Can Payers, Life Science Companies, and Others Do with ICER Analytics?
Insurers, health systems, and pharmacy benefit managers can use ICER Analytics in formulary development and adoption, internal assessment and P&T committee prep, long-term value and budget impact modeling, and development of outcomes-based agreements.
Life sciences companies can use ICER Analytics to formulate a pre-market research or pricing strategy, inform market access strategy at launch and post-market, and catalyze the shift to a “Total Cost of Care” focus.
Many others will find their own goals advanced by use of ICER Analytics, from patient groups seeking a full seat at the table with payers or life science companies to discuss pricing and access; to employers who wish to have a tool to evaluate their own benefit design options and to be able to query their PBMs and insurers on how maximum value is being achieved; to financial analysts and investors who want to forecast threshold pricing or threshold effectiveness targets for emerging drugs based on previous economic modeling efforts.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.